EE9800250A - Teraapias kasutatavad karbaamhapete asabitsüklilised estrid - Google Patents

Teraapias kasutatavad karbaamhapete asabitsüklilised estrid

Info

Publication number
EE9800250A
EE9800250A EE9800250A EE9800250A EE9800250A EE 9800250 A EE9800250 A EE 9800250A EE 9800250 A EE9800250 A EE 9800250A EE 9800250 A EE9800250 A EE 9800250A EE 9800250 A EE9800250 A EE 9800250A
Authority
EE
Estonia
Prior art keywords
therapy
acids used
carbamic acids
azabicyclic
esters
Prior art date
Application number
EE9800250A
Other languages
English (en)
Inventor
Macor John
Wu Edwin
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9800250A publication Critical patent/EE9800250A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EE9800250A 1996-02-23 1997-02-21 Teraapias kasutatavad karbaamhapete asabitsüklilised estrid EE9800250A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy
PCT/SE1997/000294 WO1997030998A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy

Publications (1)

Publication Number Publication Date
EE9800250A true EE9800250A (et) 1999-02-15

Family

ID=20401517

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800250A EE9800250A (et) 1996-02-23 1997-02-21 Teraapias kasutatavad karbaamhapete asabitsüklilised estrid

Country Status (27)

Country Link
US (2) US5998429A (et)
EP (1) EP0885221B1 (et)
JP (1) JP2000505452A (et)
KR (1) KR19990087184A (et)
CN (1) CN1063749C (et)
AR (1) AR005876A1 (et)
AT (1) ATE219081T1 (et)
AU (1) AU706944B2 (et)
BR (1) BR9707616A (et)
CA (1) CA2246051A1 (et)
CZ (1) CZ289110B6 (et)
DE (1) DE69713295T2 (et)
EE (1) EE9800250A (et)
HK (1) HK1017357A1 (et)
HU (1) HUP9901273A3 (et)
ID (1) ID15969A (et)
IL (2) IL125620A (et)
IS (1) IS4830A (et)
NO (1) NO983711L (et)
NZ (1) NZ331145A (et)
PL (1) PL328614A1 (et)
RU (1) RU2172739C2 (et)
SE (1) SE9600683D0 (et)
SK (1) SK102798A3 (et)
TR (1) TR199801642T2 (et)
WO (1) WO1997030998A1 (et)
ZA (1) ZA971082B (et)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016357A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
AU2001282910A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
EP1419162A1 (en) * 2001-08-24 2004-05-19 Pharmacia & Upjohn Company Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
US20030105089A1 (en) * 2001-09-12 2003-06-05 Wishka Donn G. Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
GEP20063814B (en) * 2001-10-02 2006-05-10 Upjohn Co Azabicyclic-Substituted Fused-Heteroaryl Compounds for Treatment of DiseaseAzabicyclic-Substituted Fused-Heteroaryl Compounds for Treatment of Disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
JP2005510523A (ja) * 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
BR0214929A (pt) 2001-12-14 2006-05-30 Targacept Inc métodos e composições para o tratamento de distúrbios do sistema nervoso central
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
US6894042B2 (en) * 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
US6858613B2 (en) * 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
US7001900B2 (en) * 2002-02-20 2006-02-21 Pfizer Inc. Azabicyclic compounds for the treatment of disease
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
EP2298759A1 (en) 2002-08-30 2011-03-23 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7429664B2 (en) 2002-09-25 2008-09-30 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
AU2003269401A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
PT1949901E (pt) * 2002-12-06 2014-05-23 The Feinstein Inst Medical Res Método para a determinação de um agonista colinérgico selectivo para um receptor nicotínico alfa 7
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
MXPA05010496A (es) * 2003-03-28 2005-11-16 Pharmacia & Upjohn Co Llc Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE10334724A1 (de) 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
PL1678172T3 (pl) 2003-10-15 2010-05-31 Targacept Inc Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
NZ548228A (en) 2003-12-22 2009-04-30 Memory Pharm Corp Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ATE455776T1 (de) 2004-12-22 2010-02-15 Memory Pharm Corp Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
CA2593079C (en) 2004-12-27 2014-08-19 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
AU2006283453A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2119716A4 (en) * 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
CN101883771A (zh) 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
BRPI0907570A2 (pt) 2008-02-13 2019-09-24 Targacept Inc agonistas alfa7 nicotínico e antipsicóticos
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2012516326A (ja) * 2009-01-28 2012-07-19 アストラゼネカ・アクチエボラーグ ２−アザ−ビシクロ［２．２．１］ヘプタン化合物及びそれらの使用
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
FR2948368B1 (fr) * 2009-07-21 2011-07-22 Servier Lab Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP3636314B1 (en) 2009-12-23 2021-09-08 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
SI3029039T1 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
EP2970251B1 (en) 2013-03-15 2019-02-27 Genzyme Corporation Method of preparing glucosylceramide synthase inhibitors
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
DE102017210141A1 (de) 2017-06-16 2018-12-20 Henkel Ag & Co. Kgaa Portion zur Bereitstellung tensidhaltiger Flotten
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2021096241A1 (en) * 2019-11-15 2021-05-20 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
KR20210059632A (ko) * 2019-11-15 2021-05-25 주식회사유한양행 신규의 2,3-다이하이드로-1h-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
JP2023526080A (ja) 2020-05-21 2023-06-20 ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ 迷走神経刺激のためのシステムおよび方法
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat
IL306116A (en) * 2021-05-11 2023-11-01 Yuhan Corp New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them
WO2024090919A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
WO2024090917A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817121U1 (de) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives

Also Published As

Publication number Publication date
JP2000505452A (ja) 2000-05-09
EP0885221B1 (en) 2002-06-12
HK1017357A1 (en) 1999-11-19
WO1997030998A1 (en) 1997-08-28
NO983711D0 (no) 1998-08-13
IS4830A (is) 1998-08-20
TR199801642T2 (xx) 1998-11-23
AR005876A1 (es) 1999-07-21
ATE219081T1 (de) 2002-06-15
SK102798A3 (en) 1999-01-11
ID15969A (id) 1997-08-21
AU2238797A (en) 1997-09-10
HUP9901273A3 (en) 2000-06-28
CZ289110B6 (cs) 2001-11-14
NZ331145A (en) 2000-02-28
PL328614A1 (en) 1999-02-01
SE9600683D0 (sv) 1996-02-23
IL125620A0 (en) 1999-04-11
AU706944B2 (en) 1999-07-01
CN1063749C (zh) 2001-03-28
IL125620A (en) 2001-09-13
US5998429A (en) 1999-12-07
NO983711L (no) 1998-08-13
IL137585A0 (en) 2001-07-24
CZ265998A3 (cs) 2000-02-16
CN1211983A (zh) 1999-03-24
DE69713295T2 (de) 2003-01-09
KR19990087184A (ko) 1999-12-15
ZA971082B (en) 1997-08-25
CA2246051A1 (en) 1997-08-28
BR9707616A (pt) 1999-07-27
EP0885221A1 (en) 1998-12-23
HUP9901273A2 (hu) 1999-07-28
DE69713295D1 (de) 2002-07-18
RU2172739C2 (ru) 2001-08-27
US6054464A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
EE9800250A (et) Teraapias kasutatavad karbaamhapete asabitsüklilised estrid
DE68928033D1 (de) Stereosynthesizer und entsprechendes verfahren
ID15827A (id) Pembuatan asam akrilik dan ester
FI940874A0 (fi) Menetelmä maitohapon ja maitohappoestereiden valmistamiseksi
AU4342989A (en) Mercapto-acylamino acids useful in the treatment of cardiovascular disorders and as analgesics
ITMI912432A0 (it) Procedimento e apparecchiatura per la fermentazione di amminoacidi
DE59500266D1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
DE59711379D1 (de) Oral applizierbare formulierungen von chinolon- oder naphthyridoncarbonsäuren
NO950936D0 (no) 5-vinyl- og 5-etinylchinolon- og naftyridonkarboksylsyrer
NO972103L (no) Eleutherobin og analoger av denne
ZA885328B (en) Phenylalkenylcarboxylic acids and their esters
DK295386A (da) 3-substitueret propenylaminothiazolyl-cephalosporansyrer og estere deraf
KR970006271A (ko) 피로카르본산 디에스테르 및 그의 제조방법 및 용도
DE69708032D1 (de) Verfahren zur Herstellung von Trimethylcatecholdiestern
NO931011D0 (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
NO980811D0 (no) Blanding av estere og anvendelse derav
DE59010296D1 (de) Polyethercarbonsäureester und ihre Herstellung
IT1186768B (it) Acilammino idrossialcanoil ammino ed immino acidi ed esteri
DE69600338D1 (de) Verfahren zur Herstellung von Naphthalin-2,6-dicarbonsäure und ihrem Ester
KR960023568U (ko) 볼 조인트의 구조와 형상
NO179410C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive monobenzofyriner og anvendelse av disse
FI972791A (fi) Orgaanisten happojen ja aminohappojen valmistus
DK349687A (da) 7beta-(substituerede)-amino-3-substituerede cephalosporansyrer og estere deraf
KR980000001U (ko) 오락 및 연습용 당구대
SE9604300D0 (sv) Therapeutical use and method